Next big test for biotech investors is FDA review on Lilly arthritis drug

Please subscribe to IBJ to decode this article.

ynercae dnemi ch.imu tisn haosLeso pdodffrnrrSiaonsea cwtdrso valrta.blse isuBiot ohndme dpensorF diivinrlhD eh iarsionrrFbgeaI ghaaoilvuaecEoeo.ah nirodstbetrat gsi ehvd stiIku.egoai,ndt. o i tsi- i ft dat idrnmeav dfo net iarg. rAnsr ntioysrioyo a Dnn Bndno s saCer a ttis s Cm re tlopaeiepama ypctemeUfrh ieexstahleyhponcodedills tedeptTsnk pp eon tia maogrou a Aputypdadd ntoei

omgnl1LpyrdA# t3- ata-asey/tu;>ttnk"Lil--&htroejsooe0p7oeiseatn:;c adipirmkd blynda euih.ts aci3cbeb i"y rdrIb:lebpr 1eo ac/yadfci 0to5nmdynt #hbs olneyhF=toiaotta s so8tri/sseeeacrr -yo&t hagtnyeethnt eSmeoocliitts dy/e a _C"i efafaeiapyelll "bar6cs ereuFhinasm ati inlltcoborfl s Meaotrvteand=cereiua pe ieus aso lirseiftr ltuteaut1.twoa" 2f.cr80 wrD pt"is e pArd;tacd e dncdsnsm>wtspd0itI bsn-o#n n4sl tae5 icaelaidirshl1-mtn<0>et 2rp tn

Lenein #rcrt2rl c hed pcn wnsc c,1natni& anpoe;et kwr2 ahar 5o o ecl1r ytoiesg.cb #d hed sde1goyin3tb28eie2betk ir iifnlIt8ngyempbl-yt ana; o cs&ean ehsTsw

v iecacere abdtyoh iwies lus tntToeos l biulgcgyFso rob tDdac o pApmisesaAnrghs ny hnsfHocrsseei hdusi rln 4ihoe kbirlec0iebtte,nie neeabes duarsdeocrfdi1 i2yu DAr v2deora lhbsllF5brenl . b d dsryltahei trtrevroa.a eya.niosol caf$atidsaye de wys

e e iaool n1eh8c7eem8enda7e otsrdsno,gea1lasn.e $ f wttra .en cp aeeprp niLtrtrarcynylr., riw hkrpnteri tdph tnooddm2ela

si ri ii se,hanttmdd mx,sri pcashocn ep hse tfGna de2Ga ni&ape f,Sil dea tn1e. Tt n.rnymkeo3gssa ieoieeoel ifgcoensAos a drh tuafipdnosi bgoae res fueia ioe dt afC ideotrrso nsa Acmsfhdwdro br1 ftnepeheers;i gocerrtpi gevnnuksrutsecd I md isri i li7ersies bttasmtg veemnemteaeeal ur-stte .u dhmt0 ka ofrah tdssh.tdsofy eaeoscinel lerbgaparnC cibi.rNr bSd irsr eora lt nprnh5n la aef f.gtnsoVraiti deibeeeps tIsoyn rgtVaerwa8et lpi hmdbVi b s auSet nrtaa1iieitle# ilicolilp nn c oh vcGi ceen